Acquisitions, License And Research Agreements (Tables)

12 Months Ended

Dec. 31, 2011

DuoCort Pharma AB [Member]

Schedule Of Consideration Transferred

	(in thousands)
Cash	$	32,121
Contingent Consideration		21,027
Total	$	53,148

The total consideration was allocated to the net assets acquired and liabilities assumed as follows:

	(in thousands)
Assets acquired:
Cash	$	80
Inventory		246
Other current assets		591
Product rights		63,821
Goodwill		7,264
Total assets	$	72,002
Liabilities assumed:
Trade and other payables	$	1,721
Loans payable		301
Deferred tax liabilities		16,832
Total liabilities	$	18,854
Consideration transferred	$	53,148

Auralias [Member]

Schedule Of Consideration Transferred

	(in thousands)
Cash	$	14,514
Contingent Consideration		9,000
Total purchase price	$	23,514

The total cost of the acquisition was allocated to Auralis assets acquired and liabilities assumed as follows:

	(in thousands)
Assets acquired:
Cash	$	1,362
Trade receivable		741
Inventory		1,623
Property, plant and equipment		23
Contract rights		11,600
IPR&D		10,500
Goodwill		5,851
Deferred tax assets		317
Total assets	$	32,017
Liabilities assumed:
Trade and other payables	$	519
Loan Payable		1,545
Deferred tax liabilities		6,439
Total liabilities	$	8,503
Total purchase price	$	23,514